Canada's Pharmacy Overhaul: AI, New Drugs, and the Race to Modernize

TORONTO, ON – April 14, 2026 – Canadian pharmacies are at a critical inflection point, caught between the promise of a high-tech future and the persistent challenges of an overburdened healthcare system. A new report from TELUS Health reveals that while forces like artificial intelligence, automation, and direct-to-consumer drug models are rapidly accelerating the need for change, the sector is struggling to keep pace, creating a widening gap between awareness and adoption.

The 2026 Pharmacy Trends Report, based on a survey of over 150 retail pharmacists, paints a picture of an industry under pressure. As pharmacists increasingly step in to fill primary care gaps for the roughly six million Canadians without a family doctor, their capacity to take on greater clinical responsibilities is being tested.

"Pharmacists are taking on greater responsibility for treating minor ailments, chronic disease support and patient counselling, so we must focus on adopting systems that support this care and pace of change," said Ratcho Batchvarov, Vice-President, Provider Solutions at TELUS Health. "The next phase of pharmacy modernization will depend on reliable technology and workflows that reduce friction, improve coordination and give pharmacists more time to focus on patient care."

The AI Paradox: High Hopes, Low Adoption

Nowhere is the gap between potential and reality more apparent than with artificial intelligence. The report identifies AI integration as the most significant driver of change, with 47 percent of pharmacists acknowledging its importance. Yet, a starkly contrasting figure reveals that only three percent of pharmacists are currently using AI tools most of the time.

This isn't due to a lack of interest in what AI can offer. Pharmacists are keenly aware of how the technology could alleviate their mounting administrative burdens. A significant majority expressed interest in AI tools for workflow automation in dispensing (72 percent), drug interaction screening (72 percent), and optimizing billing and adjudication (70 percent). These are the time-consuming, repetitive tasks that often pull pharmacists away from direct patient interaction.

The primary roadblocks to adoption are practical and significant. Pharmacists cited unreliable outputs (62 percent) and challenges with system integration (45 percent) as major barriers. The findings suggest that generic, off-the-shelf AI solutions are failing to meet the specific, high-stakes needs of a clinical environment. According to the report, purpose-built AI tools designed specifically for pharmacy and administrative tasks report an effectiveness rate between 55 and 75 percent, compared to just 38 percent for generic AI tools. This highlights a critical need for specialized, reliable, and seamlessly integrated solutions before widespread adoption can occur.

The GLP-1 Revolution and Digital Disruptors

While internal processes lag, external market forces are dramatically reshaping the competitive landscape. The report pinpoints the arrival of generic GLP-1 therapies—a class of drugs including popular metabolic and weight-loss medications like Ozempic—as a key catalyst for transformation. With patents for semaglutide expiring, the Canadian market is bracing for an influx of more affordable generic versions, which is expected to significantly increase patient access and demand.

This development is supercharging the growth of direct-to-consumer (DTC) digital pharmacy models. Companies like Pocketpills and Felix Health, which offer online consultations, prescriptions, and direct-to-door delivery, are perfectly positioned to capture this expanding market. Their emphasis on convenience and accessibility presents a formidable challenge to traditional brick-and-mortar pharmacies.

This rising competition from manufacturers and digital platforms building their own consumer channels is forcing a strategic reckoning within the sector. Traditional pharmacies can no longer rely solely on their physical presence and dispensing services. The report suggests that to remain relevant, they must modernize their own operations, enhance their digital offerings, and provide a level of personalized, clinical care that purely online models cannot easily replicate.

Modernization in Action: Central Fill and the Evolving Pharmacist

In response to these pressures, pharmacies are beginning to embrace technologies that fundamentally restructure their workflow. Central fill—large-scale, automated facilities that handle routine prescription dispensing for multiple pharmacies—is emerging as core infrastructure. Twenty-two percent of pharmacists identified it as a high-impact trend, and those already using it report significant benefits: 64 percent see reduced dispensing time, while 58 percent note both higher volume capacity and more time for patient counselling and clinical services.

By offloading the mechanical task of pill counting and packaging, central fill liberates pharmacists to practice at the top of their license. This shift is crucial as provincial governments continue to expand the scope of practice for pharmacists, empowering them to prescribe for minor ailments, manage chronic conditions, and administer a wider range of vaccinations. This evolution positions them as vital, accessible hubs within Canada's healthcare ecosystem.

However, other areas of digital integration show significant room for growth. The report found that 39 percent of pharmacists never use business intelligence tools, and only five percent use them daily, indicating a major missed opportunity to turn available data into actionable insights for patient care and business efficiency. Similarly, while e-prescribing and telepharmacy services are gaining traction, their full potential remains largely untapped.

Looking ahead, pharmacists see these trends becoming increasingly interconnected. Over the next five years, 70 percent expect central fill models integrated with automation and AI to drive even greater efficiency, while 61 percent believe it will enable a stronger focus on clinical services.

"Technology and new drug availability is accelerating new models of pharmacy care," Batchvarov added. "The administration of generic metabolic therapies requires individualized support, from virtual support and compounding services to more personalized, digitally enabled services. That raises the bar for the entire sector and reinforces why connected data, smarter workflows and more efficient operations matter so much."

The findings from the report are set to inform critical discussions at the upcoming TELUS Health Annual Conference, where industry leaders will debate the path forward for a sector in the midst of a profound transformation. The challenge is clear: pharmacies must bridge the digital divide and embrace new service models to meet the complex health needs of Canadians in a rapidly changing world.